NASDAQ:TTHI - Transition Therapeutics Stock Price, Price Target & More

$1.52 0.00 (0.00 %)
(As of 04/25/2018 04:00 PM ET)
Previous Close$1.52
Today's Range$1.52 - $1.57
52-Week Range$0.66 - $2.75
Volume12,400 shs
Average Volume70,238 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Transition Therapeutics (NASDAQ:TTHI)

Transition Therapeutics logoTransition Therapeutics Inc. is a product-focused biopharmaceutical company. The Company's principal business activity is the researching and developing of therapeutic agents. The Company is developing therapeutics for central nervous system (CNS) and metabolic disease indications. The Company's technologies are focused on the treatment of agitation and aggression in Alzheimer's disease and diabetes. The Company's subsidiary, Transition Therapeutics Ireland Limited (Transition Ireland), is developing two drug candidates: neuropsychiatric candidate ELND005 and androgen deficiency candidate TT701. The Company's subsidiary, Waratah Pharmaceuticals Inc. (Waratah), is developing diabetes drug candidate TT401. The Company's other two entities provide development services in support of the clinical and non-clinical activities of Transition Ireland and Waratah.

Receive TTHI News and Ratings via Email

Sign-up to receive the latest news and ratings for TTHI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:TTHI
CUSIPN/A
Phone+1-416-2607770

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-58.00%
Return on Assets-47.29%

Miscellaneous

EmployeesN/A
Outstanding Shares38,880,000

How to Become a New Pot Stock Millionaire

Transition Therapeutics (NASDAQ:TTHI) Frequently Asked Questions

What is Transition Therapeutics' stock symbol?

Transition Therapeutics trades on the NASDAQ under the ticker symbol "TTHI."

How were Transition Therapeutics' earnings last quarter?

Transition Therapeutics Inc (NASDAQ:TTHI) released its quarterly earnings data on Tuesday, September, 15th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.39) by $0.08. View Transition Therapeutics' Earnings History.

Has Transition Therapeutics been receiving favorable news coverage?

Media headlines about TTHI stock have been trending positive on Wednesday, according to Accern Sentiment. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Transition Therapeutics earned a coverage optimism score of 0.42 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 43.95 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of Transition Therapeutics?

Shares of TTHI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Transition Therapeutics' stock price today?

One share of TTHI stock can currently be purchased for approximately $1.52.

How can I contact Transition Therapeutics?

Transition Therapeutics' mailing address is 101 College St Suite 220, TORONTO, ON M5G 1L7, Canada. The biopharmaceutical company can be reached via phone at +1-416-2607770.


MarketBeat Community Rating for Transition Therapeutics (TTHI)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  72 (Vote Outperform)
Underperform Votes:  136 (Vote Underperform)
Total Votes:  208
MarketBeat's community ratings are surveys of what our community members think about Transition Therapeutics and other stocks. Vote "Outperform" if you believe TTHI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TTHI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Transition Therapeutics (NASDAQ:TTHI) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/AN/A
Consensus Rating Score: N/AN/AN/AN/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Transition Therapeutics (NASDAQ:TTHI) Consensus Price Target History

Price Target History for Transition Therapeutics (NASDAQ:TTHI)

Transition Therapeutics (NASDAQ:TTHI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2016CowenReiterated RatingHoldN/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Transition Therapeutics (NASDAQ:TTHI) Earnings History and Estimates Chart

Earnings by Quarter for Transition Therapeutics (NASDAQ:TTHI)

Transition Therapeutics (NASDAQ TTHI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2016Q3 2016($0.08)ViewN/AView Earnings Details
2/9/2016Q2 2016($0.04)ViewN/AView Earnings Details
11/10/2015Q1 2016($0.09)ViewN/AView Earnings Details
9/15/2015Q415($0.39)($0.31)ViewN/AView Earnings Details
5/12/2015Q315($0.20)($0.11)ViewN/AView Earnings Details
2/10/2015($0.24)($0.38)ViewN/AView Earnings Details
11/12/2014Q312($0.18)($0.45)ViewN/AView Earnings Details
9/26/2014($0.28)($0.39)ViewN/AView Earnings Details
5/14/2014($0.07)($0.16)ViewN/AView Earnings Details
2/12/2014Q2 2014($0.11)($0.04)ViewN/AView Earnings Details
11/12/2013($0.11)($0.08)ViewN/AView Earnings Details
9/11/2013Q4 2013$0.15$0.17$7.00 million$6.90 millionViewN/AView Earnings Details
5/7/2013Q3 2013($0.11)ViewN/AView Earnings Details
2/7/2013Q2 2013($0.11)($0.10)ViewN/AView Earnings Details
11/8/2012Q1 2013$0.29ViewN/AView Earnings Details
9/13/2012Q4 2012($0.10)ViewN/AView Earnings Details
5/8/2012Q3 2012($0.19)($0.11)ViewN/AView Earnings Details
2/9/2012Q2 2012($0.17)($0.15)ViewN/AView Earnings Details
12/1/2011Q1 2012($0.15)($0.12)ViewN/AView Earnings Details
9/19/2011Q4 2011($0.22)($0.17)ViewN/AView Earnings Details
5/10/2011Q3 2011($0.01)($0.14)ViewN/AView Earnings Details
2/7/2011Q2 2011$0.23$1.05ViewN/AView Earnings Details
11/11/2010Q1 2011($0.21)($0.19)ViewN/AView Earnings Details
9/27/2010Q4 2010($0.21)($0.20)ViewN/AView Earnings Details
5/10/2010Q3 2010($0.17)($0.13)ViewN/AView Earnings Details
2/10/2010Q2 2010($0.20)ViewN/AView Earnings Details
11/10/2009Q1 2010($0.28)($0.23)ViewN/AView Earnings Details
5/13/2009Q3 2009($0.28)($0.31)ViewN/AView Earnings Details
2/11/2009Q2 2009($0.24)($0.17)ViewN/AView Earnings Details
11/10/2008Q1 2009($0.21)($0.21)ViewN/AView Earnings Details
5/14/2008Q3 2008($0.17)($0.22)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Transition Therapeutics (NASDAQ:TTHI) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Transition Therapeutics (NASDAQ TTHI) Insider Trading and Institutional Ownership History

Insider Trading History for Transition Therapeutics (NASDAQ:TTHI)
Insider Trading History for Transition Therapeutics (NASDAQ:TTHI)

Transition Therapeutics (NASDAQ TTHI) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
(Data available from 1/1/2013 forward)

Headlines

Transition Therapeutics (NASDAQ TTHI) News Headlines

Source:
DateHeadline
Financial Analysis: Baxalta (BXLT) versus Transition Therapeutics (TTHI)Financial Analysis: Baxalta (BXLT) versus Transition Therapeutics (TTHI)
www.americanbankingnews.com - March 22 at 5:41 AM
Reviewing Anika Therapeutics (ANIK) & Transition Therapeutics (TTHI)Reviewing Anika Therapeutics (ANIK) & Transition Therapeutics (TTHI)
www.americanbankingnews.com - February 23 at 3:26 PM
Head to Head Review: Fortress Biotech (FBIO) and Transition Therapeutics (TTHI)Head to Head Review: Fortress Biotech (FBIO) and Transition Therapeutics (TTHI)
www.americanbankingnews.com - January 20 at 11:24 AM
Alimera Sciences (ALIM) versus Transition Therapeutics (TTHI) Head-To-Head ComparisonAlimera Sciences (ALIM) versus Transition Therapeutics (TTHI) Head-To-Head Comparison
www.americanbankingnews.com - December 29 at 1:56 AM
Transition Therapeutics (TTHI) versus KalVista Pharmaceuticals (KALV) Head to Head ReviewTransition Therapeutics (TTHI) versus KalVista Pharmaceuticals (KALV) Head to Head Review
www.americanbankingnews.com - November 24 at 11:40 AM
Contrasting Sonoma Pharmaceuticals (SNOA) & Transition Therapeutics (TTHI)Contrasting Sonoma Pharmaceuticals (SNOA) & Transition Therapeutics (TTHI)
www.americanbankingnews.com - November 4 at 9:28 PM
Head to Head Analysis: Transition Therapeutics (TTHI) and MediWound (MDWD)Head to Head Analysis: Transition Therapeutics (TTHI) and MediWound (MDWD)
www.americanbankingnews.com - October 26 at 5:34 AM
Roger Crystal Went to Business School to Learn How to Treat AddictionRoger Crystal Went to Business School to Learn How to Treat Addiction
www.bloomberg.com - October 25 at 1:40 AM
Analyzing Transition Therapeutics (TTHI) & Its RivalsAnalyzing Transition Therapeutics (TTHI) & Its Rivals
www.americanbankingnews.com - October 16 at 12:08 AM
Analyzing Transition Therapeutics (TTHI) and Kamada (KMDA)Analyzing Transition Therapeutics (TTHI) and Kamada (KMDA)
www.americanbankingnews.com - September 23 at 12:26 AM
Critical Contrast: Transition Therapeutics (TTHI) and Its RivalsCritical Contrast: Transition Therapeutics (TTHI) and Its Rivals
www.americanbankingnews.com - September 19 at 4:26 PM
Financial Survey: Catalyst Biosciences (CBIO) vs. Transition Therapeutics (TTHI)Financial Survey: Catalyst Biosciences (CBIO) vs. Transition Therapeutics (TTHI)
www.americanbankingnews.com - August 25 at 4:30 PM
Transition Therapeutics (NASDAQ:TTHI) and Peregrine Pharmaceuticals (PPHM) Head to Head SurveyTransition Therapeutics (NASDAQ:TTHI) and Peregrine Pharmaceuticals (PPHM) Head to Head Survey
www.americanbankingnews.com - August 12 at 2:04 PM
Head-To-Head Survey: Transition Therapeutics (TTHI) vs. Onconova Therapeutics (ONTX)Head-To-Head Survey: Transition Therapeutics (TTHI) vs. Onconova Therapeutics (ONTX)
www.americanbankingnews.com - August 12 at 12:30 AM
OPKO Health (OPK) Announces Transition Therapeutics (TTHI) Shareholder Approval of Proposed AcquisitionOPKO Health (OPK) Announces Transition Therapeutics (TTHI) Shareholder Approval of Proposed Acquisition
www.streetinsider.com - August 26 at 10:49 AM
Transition Therapeutics (TTHI) Commences Dosing in TT701 Phase 2 in Androgen Deficiency - StreetInsider.comTransition Therapeutics (TTHI) Commences Dosing in TT701 Phase 2 in Androgen Deficiency - StreetInsider.com
www.streetinsider.com - April 26 at 9:48 AM
Transition: Lilly Not To Advance Diabetes Drug Candidate TT401 To Phase 3Transition: Lilly Not To Advance Diabetes Drug Candidate TT401 To Phase 3
www.nasdaq.com - April 18 at 9:57 AM
Transition Therapeutics (TTHI) Says Lilly (LLY) Wont Advance TT401 into Phase 3Transition Therapeutics (TTHI) Says Lilly (LLY) Won't Advance TT401 into Phase 3
www.streetinsider.com - April 18 at 9:57 AM
Transition Therapeutics Provides Update On Type 2 Diabetes Drug Candidate TT401Transition Therapeutics Provides Update On Type 2 Diabetes Drug Candidate TT401
www.thestreet.com - April 18 at 6:34 AM

SEC Filings

Transition Therapeutics (NASDAQ:TTHI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Transition Therapeutics (NASDAQ:TTHI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Transition Therapeutics (NASDAQ TTHI) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.